Apimeds Pharmaceuticals US, Inc. (APUS) — Cash Flow-to-Debt Ratio
Apimeds Pharmaceuticals US, Inc. (APUS) has a Cash Flow-to-Debt Ratio of -1.58x as of September 2025, meaning its operating cash flow of $-1.73 Million could theoretically repay -2% of its total liabilities ($1.09 Million) in one year. See Apimeds Pharmaceuticals US, Inc. (APUS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Apimeds Pharmaceuticals US, Inc. Cash Flow-to-Debt Ratio (2021–2024)
Historical debt coverage capacity for Apimeds Pharmaceuticals US, Inc. across 4 annual periods. Also explore Apimeds Pharmaceuticals US, Inc. equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Apimeds Pharmaceuticals US, Inc. (2021–2024)
Year-by-year debt coverage analysis for Apimeds Pharmaceuticals US, Inc.. For market capitalisation and broader financial context, see APUS market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.53x | $-733.53K | $1.37 Million | ▲ +66.7% |
| 2023 | -1.61x | $-627.79K | $390.20K | ▼ -158.4% |
| 2022 | -0.62x | $-448.17K | $719.78K | ▲ +68.9% |
| 2021 | -2.00x | $-823.11K | $410.65K | — |